📊 KRYS Key Takeaways
Is Krystal Biotech, Inc. (KRYS) a Good Investment?
Krystal Biotech exhibits exceptional financial strength with 52.6% net margins, 41.5% operating margins, and robust 188.9M free cash flow generation. The company maintains a fortress balance sheet with minimal debt (4.3M), substantial cash reserves (496.3M), and exceptional liquidity (9.95x current ratio), providing significant strategic flexibility. However, net income growth (129.7% YoY) significantly outpacing revenue growth (33.9%) requires validation of sustainability before higher conviction.
Krystal Biotech shows standout fundamentals with 33.9% revenue growth, exceptional operating (41.5%) and net (52.6%) margins, strong ROE/ROA, and a 48.5% FCF margin. A cash-rich, near-debt-free balance sheet supports continued investment, with upside if revenue proves recurring rather than milestone-driven.
Why Buy Krystal Biotech, Inc. Stock? KRYS Key Strengths
- Fortress balance sheet with minimal leverage (0.00x debt/equity), 496.3M cash reserves, and exceptional liquidity ratios (9.95x current, 9.56x quick) providing substantial financial flexibility and downside protection
- Exceptional profitability metrics with 52.6% net margin and 41.5% operating margin demonstrating strong pricing power and operational efficiency
- Robust free cash flow generation of 188.9M with 48.5% FCF margin and low capital intensity (12.0M CapEx) indicating highly cash-generative business model
- Solid revenue growth of 33.9% YoY with net income surge of 129.7%, suggesting significant operating leverage and margin expansion
- Exceptional profitability and cash generation (operating margin 41.5%, FCF margin 48.5%).
- Robust liquidity and minimal leverage (current ratio 9.95x; negligible debt).
- Healthy returns on capital (ROE 16.8%, ROA 15.4%).
KRYS Stock Risks: Krystal Biotech, Inc. Investment Risks
- Net income growth (129.7% YoY) substantially exceeds revenue growth (33.9%), indicating potential one-time gains, accounting benefits, or unsustainable cost reductions that require validation of recurring nature
- Gross margin data unavailable prevents assessment of underlying product profitability and true operational performance quality; unusually high net margin warrants scrutiny
- Biotech sector inherent risks including regulatory approval delays, clinical trial failures, patent expiration, competitive pressures, and R&D project attrition could materially impact future revenue and margins
- Revenue durability and concentration risk typical of early commercial biotechs.
- Potential non-recurring or milestone revenue inflating margins (gross margin N/A).
- Pricing/reimbursement and regulatory/manufacturing execution could pressure growth.
Key Metrics to Watch
- Gross margin trend and composition - critical to understanding true profitability and sustainability of exceptional net margins
- Net income sustainability analysis - determine if 129.7% growth derived from operating leverage, one-time items, or recurring operations
- Revenue growth trajectory - monitor if 33.9% growth rate sustains, accelerates, or decelerates in subsequent reporting periods
- Revenue mix: recurring product vs one-time/milestone.
- Operating margin sustainability (target >=35%).
Krystal Biotech, Inc. (KRYS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 48.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 9.95x current ratio provides a solid financial cushion.
KRYS Profit Margin, ROE & Profitability Analysis
KRYS vs Healthcare Sector: How Krystal Biotech, Inc. Compares
How Krystal Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Krystal Biotech, Inc. Stock Overvalued? KRYS Valuation Analysis 2026
Based on fundamental analysis, Krystal Biotech, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Krystal Biotech, Inc. Balance Sheet: KRYS Debt, Cash & Liquidity
KRYS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Krystal Biotech, Inc.'s revenue has grown significantly by 668% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.39 reflects profitable operations.
KRYS Revenue Growth, EPS Growth & YoY Performance
KRYS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $83.8M | $932.0K | $0.91 |
| Q2 2025 | $70.3M | $932.0K | $0.53 |
| Q1 2025 | $45.3M | $932.0K | $0.03 |
| Q3 2024 | $8.6M | $932.0K | $0.08 |
| Q2 2024 | N/A | $932.0K | $0.53 |
| Q1 2024 | N/A | $932.0K | $0.03 |
| Q3 2023 | N/A | $2.2M | $0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Krystal Biotech, Inc. Dividends, Buybacks & Capital Allocation
KRYS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Krystal Biotech, Inc. (CIK: 0001711279)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KRYS
What is the AI rating for KRYS?
Krystal Biotech, Inc. (KRYS) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KRYS's key strengths?
Claude: Fortress balance sheet with minimal leverage (0.00x debt/equity), 496.3M cash reserves, and exceptional liquidity ratios (9.95x current, 9.56x quick) providing substantial financial flexibility and downside protection. Exceptional profitability metrics with 52.6% net margin and 41.5% operating margin demonstrating strong pricing power and operational efficiency. ChatGPT: Exceptional profitability and cash generation (operating margin 41.5%, FCF margin 48.5%).. Robust liquidity and minimal leverage (current ratio 9.95x; negligible debt)..
What are the risks of investing in KRYS?
Claude: Net income growth (129.7% YoY) substantially exceeds revenue growth (33.9%), indicating potential one-time gains, accounting benefits, or unsustainable cost reductions that require validation of recurring nature. Gross margin data unavailable prevents assessment of underlying product profitability and true operational performance quality; unusually high net margin warrants scrutiny. ChatGPT: Revenue durability and concentration risk typical of early commercial biotechs.. Potential non-recurring or milestone revenue inflating margins (gross margin N/A)..
What is KRYS's revenue and growth?
Krystal Biotech, Inc. reported revenue of $389.1M.
Does KRYS pay dividends?
Krystal Biotech, Inc. does not currently pay dividends.
Where can I find KRYS SEC filings?
Official SEC filings for Krystal Biotech, Inc. (CIK: 0001711279) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KRYS's EPS?
Krystal Biotech, Inc. has a diluted EPS of $6.84.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KRYS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Krystal Biotech, Inc. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is KRYS stock overvalued or undervalued?
Valuation metrics for KRYS: ROE of 16.8% (sector avg: 15%), net margin of 52.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy KRYS stock in 2026?
Our dual AI analysis gives Krystal Biotech, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is KRYS's free cash flow?
Krystal Biotech, Inc.'s operating cash flow is $200.9M, with capital expenditures of $12.0M. FCF margin is 48.5%.
How does KRYS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 52.6% (avg: 12%), ROE 16.8% (avg: 15%), current ratio 9.95 (avg: 2).